AZD4635

DRUG6 trials

Sponsors

AstraZeneca, MedImmune LLC

Conditions

Advanced Solid MalignanciesCarcinoma, Non-Small-Cell LungColorectal Carcinoma (CRC)Healthy Volunteer/DDI StudyMetastatic Castrate-Resistant Prostate Carcinoma (mCRPC)Metastatic Castration-Resistant Prostate Cancer (mCRPC)Non-Small Cell Lung Cancer (NSCLC)Progressive Metastatic Castrate-Resistant Prostate Cancer

Phase 1

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

CompletedNCT02740985

AstraZenecaAdvanced Solid Malignancies, Colorectal Carcinoma (CRC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC) +1

Start: 2016-06-17End: 2023-03-31Updated: 2023-05-26

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Active, not recruitingNCT03381274

MedImmune LLCCarcinoma, Non-Small-Cell Lung

Start: 2018-05-08End: 2026-11-06Updated: 2026-07-13

A Phase I Study of AZD4635 in Japanese Patients With Advanced Solid Malignancies

CompletedNCT03980821

AstraZenecaAdvanced Solid Malignancies

Start: 2019-07-04End: 2020-09-07Updated: 2020-12-08

A Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers

CompletedNCT04478513

AstraZenecaHealthy Volunteer/DDI Study

Start: 2020-07-21End: 2020-12-23Updated: 2021-01-06

Phase 2

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

CompletedNCT04089553

AstraZenecaMetastatic Castration-Resistant Prostate Cancer (mCRPC), Prostate Cancer

Start: 2019-08-29End: 2023-04-11Updated: 2024-04-16

A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.

CompletedNCT04495179

AstraZenecaProgressive Metastatic Castrate-Resistant Prostate Cancer

Start: 2020-08-04End: 2022-08-08Updated: 2023-08-09

Related Papers

A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.

2024-03-029 citations

Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study.

2023-12-133 citations

Abstract 4135: A novel plasma cell-based mechanism of action of adenosine immunomodulation and A2AR antagonism

Cancer Research2023-04-041 citations

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Nature Communications2023-02-27209 citations

Phase 2 study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2023-02-204 citations

CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report.

2023-01-1118 citations

Abstract CT163: CD73 inhibitor oleclumab plus osimertinib for advanced EGFRm NSCLC: First report of a Phase 1b/2 study

Cancer Research2021-07-0111 citations

Phase 1 trial of the adenosine A<sub>2A</sub> receptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A<sub>2A</sub> receptor within the tumor.

Journal of Clinical Oncology2021-05-2017 citations

Abstract CT152: First in human study with EOS100850, a novel potent A2A antagonist, shows excellent tolerance and clinical benefit in immune resistant advanced cancers

Cancer Research2020-08-158 citations

Abstract CT168: Clinical pharmacology of AZD4635 (A2ARi): Integration of PK data from cancer patients (CP) and healthy volunteer (HV) clinical trials to provide dosing recommendations

Cancer Research2020-08-153 citations

A phase I, open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid malignancies: Results from prostate cancer patients (NCT02740985).

Journal of Clinical Oncology2020-05-2022 citations

Abstract A87: The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression in tumor microenvironment and enhances antitumor immunity partly by enhancing CD103+ dendritic cells

Cancer Immunology Research2020-03-012 citations

Abstract CT026: Evidence of immune activation in the first-in-human Phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors

Cancer Research2019-07-0126 citations

Abstract CT026: Evidence of immune activation in the first-in-human Phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors

Clinical Trials2019-07-016 citations

Abstract 2641: AZD4635 A2A receptor occupancy in cynomolgus monkey using PET and its application to an oncology clinical development program

Cancer Research2017-07-013 citations